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Objective: The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) 
are multisystem diseases of the small blood vessels. Patients experience irreversible damage 
and psychological effects from AAV and its treatment. An international collaboration was cre-
ated to investigate the impact of AAV on health-related quality of life (HRQoL), and develop a 
disease-specific patient-reported outcome measure to assess outcomes of importance to patients.
Methods: Patients with AAV from the UK, USA, and Canada were interviewed to identify salient 
aspects of HRQoL affected by AAV. The study was overseen by a steering committee including 
four patient research partners. Purposive sampling of interviewees ensured representation of 
a range of disease manifestations and demographics. Inductive analysis was used to identify 
themes of importance to patients; these were further confirmed by a free-listing exercise in the 
US. Individual themes were recast into candidate items, which were scrutinized by patients, 
piloted through cognitive interviews and received a linguistic and translatability evaluation.
Results: Fifty interviews, conducted to saturation, with patients from the UK, USA, and Canada, 
identified 55 individual themes of interest within seven broad domains: general health percep-
tions, impact on function, psychological perceptions, social perceptions, social contact, social 
role, and symptoms. Individual themes were constructed into >100 candidate questionnaire 
items, which were then reduced and refined to 35 candidate items.
Conclusion: This is the largest international qualitative analysis of HRQoL in AAV to date, 
and the results have underpinned the development of 35 candidate items for a disease-specific, 
patient-reported outcome questionnaire.
Keywords: ANCA-associated vasculitis, quality of life, patient-reported outcomes, granuloma-
tosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis
Introduction
Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and 
eosinophilic granulomatosis with polyangiitis (EGPA) are organ- and life-threatening 
multisystem diseases of small arteries, known as the antineutrophil cytoplasmic anti-
body (ANCA)-associated vasculitides (AAVs).1 Patients present with inflammation 
in multiple body areas, including the lungs, ear, nose, kidneys, joints, and nerves,2 
with fevers, weight loss, and fatigue.3 Treatment is with glucocorticoids and other 
immunosuppressants.4 A third of patients will have irreversible damage at diagnosis,5 
and 40% will suffer relapse.6 One-year mortality in AAV has been >15%,7 a poorer 
survival rate than breast or prostate cancer;8 however, mortality in AAV has improved, 
likely due to the adoption of newer treatment regimens.9,10 Surveys have demonstrated 
impairments in health-related quality of life (HRQoL) in AAV, in particular fatigue.3,11–18 
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A clinician-derived survey to assess patient perspectives in 
granulomatosis with polyangiitis was developed in 1998;19 
however, there have been no in-depth qualitative studies to 
capture patient perspectives on the full range of HRQoL in 
the AAVs as a whole.
Due to the relative rarity of AAV, with three overlapping 
disease phenotypes, patients with AAV are frequently con-
sidered together,4 with patients with GPA and MPA included 
within the same randomized controlled trials (RCTs).20–22 
Primary outcomes are based on the physician-based Bir-
mingham Vasculitis Activity Score,23,24 which records the 
presence or absence of disease activity.20–22,25 Patients with 
AAV, however, often have different perceptions of what is 
important to their physicians, for example, they rank fatigue 
as more important than dialysis or oxygen dependence.11 
To guage the efficacy of treatments within RCTs, validated 
measurement of both physician- and patient-focused out-
comes is key.11,26
The Outcome Measurement in Rheumatology (OMER-
ACT) Vasculitis Working Group has consistently highlighted 
the need for a disease-specific patient-reported outcome 
(PRO) measure for patients with AAV,25,27 due to concern 
that the generic Medical Outcomes Short Form-36 (SF-36) 
may not capture all themes of importance. Since OMERACT 
2012,27,28 an international collaboration (the UK, the USA, 
and Canada) has been developing an AAV disease-specific 
PRO measure, in line with the US Food and Drug Admin-
istration (FDA) guidelines for the development of PROs.29 
The development of a new PRO instrument involves three 
distinct stages with patient involvement at each step: 1) item 
generation and piloting, 2) item reduction and scale genera-
tion, and 3) testing reliability and validity. 
This paper describes the themes of importance in HRQoL 
in relation to AAV, identified through in-depth qualitative 
analysis in three countries in order to produce candidate 
questionnaire items for a new disease-specific PRO for AAV.
Methods
The study steering committee included members from the 
UK, USA, and Canada: four patient partners; medical soci-
ologists with extensive experience in PROM development, 
testing, and application; qualitative researchers; and clinical 
researchers with an interest in vasculitis. An initial conceptual 
framework was developed, through literature review and 
steering committee input, to explore domains of interest, and 
this framework evolved during the study.
A core qualitative working group (CQWG), compris-
ing researchers from the three countries, performed the 
 qualitative analysis, developed a collaborative code book of 
themes, and produced and refined candidate items. The steer-
ing committee gave critical feedback throughout on develop-
ing themes and items and the project received critical scrutiny 
at three successive Vasculitis Workshop sessions at Outcome 
Measures in Rheumatology (OMERACT) conferences.27,28
Patient study sample
Patients diagnosed with AAV were recruited from three 
rheumatology centers in the UK, USA, and Canada. Inclusion 
criteria were age ≥18, ability to give informed consent, and a 
clinically verified diagnosis of GPA, MPA, or EGPA. Patients 
were purposively sampled to assure adequate representation 
of all three diseases, chronicity of disease, different age 
ranges, sex, and organ involvement. Study approvals were 
given by the NHS Research Committee South West-Central 
Bristol, the University of Pennsylvania Office of Regulatory 
Affairs, and the Ottawa Hospital’s Research Ethics Board. 
All patients provided written informed consent.
In-depth interviews
Exploratory semi-structured patient interviews were con-
ducted to identify the range of salient aspects of HRQoL 
affected by AAV and its treatment. An interview guide of 
prompts and cues was developed by the steering committee. 
Interviews were performed by a qualitative researcher in the 
US (KK) and two clinical research fellows trained in qualita-
tive interview techniques in the UK (JCR) and Canada (NM).
Analysis
Interviews were recorded and transcribed, anonymized, 
and systematically analyzed using a modified framework 
method.30–32 Coding was carried out using both an induc-
tive (codes emerged during analysis) and deductive (codes 
anticipated) approach,33 with NVivo computer software used 
to index transcripts.34 Interviews continued until no new 
substantive themes arose indicating data saturation.35 The 
CQWG defined the themes of interest, produced a common 
thematic framework, and ensured uniformity of coding across 
sites. A proportion of transcripts from each site was double 
coded, to ensure common approaches.
Candidate item development
Members of the CQWG recast themes as candidate items, 
using patients’ descriptions throughout. Items were amended, 
and sometimes deleted by the CQWG, to reduce ambiguity and 
duplication. Piloting and further item amendment was conducted 
following feedback from steering committee patient partners.
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US participants were invited to participate in a free-listing 
activity, a semi-structured interview technique in which 
participants are given a question or statement and asked to 
identify words they associate with that phrase.36 This method 
uncovers how groups of people with shared experiences cre-
ate, associate, and categorize topics.36,37
The following questions were asked: “Which words would 
you use to describe your symptoms when your vasculitis: 1) 
first started; 2) is under control; and 3) is starting to flare?” 
Patient partners on the study team performed pile-sorting 
of the responses independently, with disagreement resolved 
through consensus. Following free-listing and pile-sorting, 
the Smith’s Salience Index (SSI)38,39 was used to identify 
the most salient terms. SSI scores were calculated using 
ARTHROPAC software. The identified salient terms were 
contrasted across interview themes to provide additional lens 
of validation for candidate item development.
Patient refinement
Three rounds of patient cognitive interviews were completed, 
in order to check understanding and interpretation of the 
candidate items.40,41 This was an iterative process, with items 
refined or rejected by the CQWG between each round.
In parallel, a readability and translatability assessment 
was completed in collaboration with a specialist UK com-
pany (Pharmaquest – translation and linguistic validation 
company for PROs).42 A breakout session was also held at 
the Vasculitis Workshop at OMERACT 2014, which sought 
feedback about 1) inclusion of contextual factors within the 
PRO and 2) attribution within the stem (or lead in sentence), 
to vasculitis and/or its treatment. All proposed item changes 
were tested by further cognitive interviews and steering 
committee review.
Results
Fifty participants, 24 men and 26 women, were interviewed 
in the UK, USA, and Canada. Participants’ characteristics are 
shown in Table 1. Interview transcripts were analyzed, iden-
tifying 55 individual themes of interest, grouped into seven 
domains (definitions of individual themes within the codebook 
in Table S1). The domains identified were general health 
perceptions, impact on function, psychological perceptions, 
social perceptions, social contact, social roles, and symptoms 
(Box 1 shows domain structure and individual themes). The 
saturation table of emergent themes is shown in Table S2.
General health perceptions
Eighty-six percent of patients used descriptions of how their 
general sense of self and wellness had been affected by 
developing AAV. Concerns about the future and difficulties 
making long-term plans were prominent, as was a sense of 
vulnerability in one’s own body.
Table 1 Demographic and disease features of 50 patients with ANCA-associated vasculitis
Demographics Oxford, 
UK (n=18)
Philadelphia, 
PA, USA (n=17)
Ottawa, ONT, 
Canada (n=15)
Total patients 
(n=50)
Sex, n (%)
Male 12 (66.7) 6 (35.3) 6 (40.0) 24 (48.0)
Female 6 (33.3) 11 (64.7) 9 (60.0) 26 (52.0)
Age, n (%)
<50 years 3 (16.7) 5 (29.4) 2 (13.3) 10 (20.0)
≥50 years 15 (83.3) 12 (70.6) 13 (86.7) 40 (80.0)
Diagnosis, n (%)
GPA 8 (44.4) 9 (52.9) 8 (53.3) 25 (50.0)
MPA 3 (16.7) 3 (17.7) 1 (6.67) 7 (14.0)
EGPA 7 (38.9) 5 (29.4) 6 (40.0) 18 (36)
Time from diagnosis, n (%)
<2 years 13 (72.2) 16 (94.1) 5 (33.3) 34 (68)
≥2 years 5 (27.8) 1 (5.88) 10 (66.7) 16 (32)
Flare <2 years, n (%)
Yes 6 (33.3) 16 (94.1) 4 (26.7) 26 (52.0)
No 12 (66.7) 1 (5.88) 11 (73.3) 24 (48.0)
Organ involvement, n (%)
Kidney 9 (50) 5 (29.4) 2 (13.3) 16 (32.0)
Lung 12 (66.7) 10 (58.8) 12 (80) 34 (68.0)
ENT 10 (55.6) 11 (64.7) 14 (93.3) 35 (70)
Neurological 4 (22.2) 6 (35.3) 1 (6.67) 12 (24)
Abbreviations: ANCA, antineutrophil cytoplasmic antibody; EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear nose and throat; GPA, granulomatosis with 
polyangiitis; MPA, microscopic polyangiitis.
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“If I compare to 3 years ago… I was the guy who was 
working 7 days a week, 16 hour days, never tired. Now… Ufff. 
It’s not the same guy anymore.” [47-year-old male with EGPA]
“I didn’t want to set foot outside the door. Simply because 
I thought … I can’t trust my body anymore”. [53-year-old 
female with EGPA]
Impact on function
Ninety percent of participants described difficulties with 
reduced levels of physical function, over 80% had a reduction 
in mobility, and 20% described difficulties in washing and 
dressing. These impairments led to frustration and impacted 
finances and work (82%), the ability to perform household 
tasks (72%), taking part in hobbies and interests (46%), and 
restricted travel (76%).
“Weakness, inability to walk, to use my arms, to bathe, to 
do anything – I just laid in bed”.  [82-year-old male with MPA]
“TV was a no-no. I got a telephone with a light on it, 
because it [the deafness] was that bad… I felt very isolated 
and very stupid”. [57-year-old male with GPA]
Psychological
Concerns about the future were highlighted in 86% of inter-
views with over 70% reporting experiencing fear, anxiety, or 
stress, and 50% describing depression or low mood. Anger or 
irritation was reported by almost 50%. Difficulties in making 
plans and the potential for premature death were described 
by patients of all ages.
“For the first year after I was diagnosed, I did nothing, 
apart from cope with me, my illness and trying to live as 
normal a life as possible”. [67-year-old female with GPA]
“I was only [age], my first year of college – everything 
is falling apart and I think I’m dying”. [36-year-old female 
with GPA]
Social perceptions
Participants were aware of the visibility of the condition, and 
its treatment side-effects, particularly in relation to glucocor-
ticoids; these issues were discussed in 64% of interviews. A 
lack of empathy from others was reported by around 60% 
of interviewees, as was being the source of worry to others.
Box 1 Domains and individual themes from patients with ANCA-associated vasculitis
Domains and individual themes of interest in ANCA-associated vasculitis, n=50 (number of interviews from which the theme 
emerged)
1. General health perceptions 3. Psychological perceptions 6. Social role
a. General sense of self and wellness (43) a. Uncertainty/concerns about future (43) a. Occupation or finances (41)
b. Lack of confidence in one’s body (27) b. Fear, anxiety, stress (37) b. Family and family planning (35)
c. Poor response to treatment (25) c. AAV dominates (33) c. Dependency on others (34)
d. Vulnerability to infection or illness (22) d. Self-efficacy (33) d. Role identity and status (25)
e. Information and knowledge (32)
2. Impact on function f. Support (29) 7. Symptoms
a. Level of physical function (45) g. Depression, low mood (25) a. Fatigue (44)
b. Personal mobility (41) h. Anger and irritation (23) b. Cognition and poor concentration (9)
c. Scope for travel (38) c. Issues related to body weight (37)
d. Household tasks (36) 4. Social perceptions d. Sleep symptoms (27)
e. Treatment consumes time/focus (33) a. Visibility of condition or side effects (34) e. Temperature instability (11)
f. Adaptation (necessary) (27) b. Empathy and emotional connections (33) f. Skin and nail problems (25)
g. Hobbies and interests (23) c. Source of other people’s worry (30) g. Earache and hearing difficulties (19)
h. Use of everyday transport (17) h. Upper respiratory tract (35)
i. Eating and drinking (16) 5. Social contact i. Eye symptoms and affected sight (22)
j. Everyday technology (10) a. Impact on social life (40) j. Cardiorespiratory symptoms (38)
k. Washing self (10) b. Social activities and participation (31) k. Gastrointestinal symptoms (18)
l. Dressing and undressing (9) c. Adaptations to facilitate social life (26) l. Muscle symptoms (16)
d. Quality of communication (14) m. Numbness and nerve symptoms (12)
e. Sex and intimate relationships (7) n. Joint symptoms (31)
o. Kidney and urinary tract (13)
p. Appetite (14)
q. Sense of taste (3)
r. Feeling unsteady or faint (13)
s.  Pain: pain unspecified (13), pain in feet and legs 
(23), pain in arms and hands (19), facial and head 
pain (18)
Abbreviation: ANCA, antineutrophil cytoplasmic antibody.
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“To have a big puffy moon face [due to glucocorticoids] 
is really hard for me. Well, you’re not attractive anymore – it’s 
weird”. [33-year-old female with GPA]
“I think some people were more supportive than others, 
and it wasn’t always the people I expected to be”. [67-year-
old female with GPA]
Social contact
Eighty percent of interviewees described an impact on their 
social life, because of fatigue, difficulties with joining in 
physical activities or communicating, or concerns about let-
ting people down by having to break plans.
“If we had a dinner date on the weekend I had to rest 
coming up to that day just to be able to have enough energy. 
I got to a point where I just didn’t bother”. [51-year-old 
female with EGPA]
“Meetings were the worst. Because I found that I was 
lip-reading. In an open room with a number of people, it was 
a nightmare”. [57-year-old male with GPA]
Social role
Eighty-two percent of participants discussed their occupa-
tion or finances, specifically stemming from difficulties with 
concentration and fatigue. Roles beyond work were also 
discussed, within the family (70%), and changes to role and 
status when having to rely on others for help (64%).
“When I was getting sick in the beginning I gave up my 
position as the executive director of the organization and I 
moved into a position with less responsibility”. [52-year-old 
female with GPA]
“It was hard on my son as well, so he started goofing off 
in school. I felt like I wasn’t a good mom, I wasn’t a good 
wife, and I was isolated”. [51-year old female with EGPA]
Symptoms
All of the patients described symptoms due to disease and 
treatment in depth. Nineteen different sets of symptoms were 
identified, most frequently fatigue (88%), cardiorespiratory 
symptoms (76%), issues related to body weight (74%), and 
upper respiratory tract symptoms (70%). A full list of symp-
toms is given in Box 1, with quotes in Box 2.
Free-listing and pile-sorting items of 
importance to patients with AAV
All 17 US patients interviewed were invited to free-list terms 
they associated with the onset, remission, and flaring of 
their AAV (Figure 1). The most salient themes at onset were 
pain and discomfort (SSI=0.37), nasal and sinus problems 
(SSI=0.32), and fatigue and energy levels (SSI=0.27). Emo-
tional effects were within the top three during flare (SSI=0.28) 
and remission (SSI=0.27). Themes identified were compared 
with the individual themes of interest and domains from the 
in-depth patient interviews and no new themes were identified 
(Box 1 for overview and Table S1 for detailed descriptions).
Candidate item development
Fifty-five individual themes were identified from the quali-
tative work (Box 1), and these were recast into an initial 
list of 105 candidate items by members of the CQWG. 
Patient descriptions informed the design of the candidate 
questionnaire items and response options, resulting in dif-
ferent sections. Patients described the overall severity of 
their symptoms, rather than the frequency; pain was usually 
described in relation to specific body areas, such as joints or 
muscles; and ability to function was described in terms of 
the amount of difficulty with completing a specific task. The 
candidate items were scrutinized for duplication and ambi-
guity of items, reducing the item pool to 42 items. Patients 
made it clear that it was difficult to tease apart symptoms 
caused by AAV versus its treatment, so both were included 
within the stem of the question. Items related to contextual 
factors (eg, support and self-efficacy – Box 1 and Table S1) 
were not included within the PRO itself, after discussion at an 
OMERACT 2014 breakout session with patient participants.28
Three rounds of cognitive interviews were conducted in 
the UK and USA, using the 42-item version of the question-
naire, with amendments after each round. Word changes were 
suggested by patients, for example, clarification of the word 
essential in relation to activities, and change to the period 
of recall from 7 days to 4 weeks. All participants reported 
that the questionnaire captured content relevant to them. 
Seven items were rejected because of ambiguity, repetition, 
or being contextual factors. Following the translatability 
assessment (Box S1), minor changes were made to a few 
items, and these revisions were piloted in the last round of 
interviews. The conceptual framework evolved in response 
to insights from the qualitative research, feedback from the 
steering committee, and breakout sessions at OMERACT, and 
the final version is shown in Figure 2. The resulting 35-item 
candidate pool is shown in Box 3.
Discussion
This is the most comprehensive evaluation of the patient per-
spective in AAV to date. Patients have been an integral part 
of this work as key members of the steering committee and 
qualitative interview participants, reflecting all three diseases, 
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differing disease manifestations, a wide demographic range, 
and three different countries. The item generation for a novel, 
disease-specific PRO measure is underpinned by this qualitative 
research, which should ensure that the final candidate items 
have good face validity within each country. Themes identified 
in previous quantitative studies are confirmed, for example, 
fatigue,13 anxiety, and depression,16 and the impact on everyday 
function and employment.17,43 Newer themes include difficulties 
in making plans, from short-term social engagements to life 
planning, previously reported in patients with systemic lupus 
erythematosus, rheumatoid arthritis, and GPA.19,44,45
The strengths of this study include a high level of patient 
involvement, and ongoing critical review through OMER-
ACT Workshops, which have helped to ensure that each 
stage was consistent with best practice. Patients were pur-
posively sampled to include a range of disease features and 
demographics, including a high proportion of patients with 
recent active disease. This was to ensure a focus on themes 
(and then items), which would exhibit greatest change in the 
context of a RCT. A third of patients had longer-standing 
disease, and saturation of themes was also reached within 
this patient group. The high rate of relapsing disease may 
also be a reflection of the fact that patients with GPA, who 
have a higher rate of relapse,46 were slightly over-represented 
compared with patients with MPA; this may be a potential 
bias of the sample. That only English-speaking participants 
were included is a limitation of this study. However, a trans-
latability assessment was performed for the questionnaire 
items, to ensure that any future translation into a range of 
languages should be straightforward.47 In addition, care was 
taken to develop items that were not overly culture-specific, 
for example, describing “difficulties with traveling far from 
home,” rather than “going on holidays.” Interviews were 
performed by clinical fellows in the UK and Canada, and this 
may have changed the way that patients described problems in 
relation to their disease or treatment. Training was, therefore, 
Box 2 Patient descriptions of symptoms of ANCA-associated vasculitis and its treatment
Fatigue: “So with the severe flares, the fatigue is indescribable. Looking back, I don’t know how I got up and went to work every day last year”. 
[30-year-old. F, GPA]
Cognition/concentration: “You feel like you have the flu, sort of achy and really tired, your head is kind of fuzzy, it’s hard to think and 
concentrate”. [52-year-old. F, GPA]
Issues related to body weight: “Taking too many prednisolone really made me eat a lot and gain weight”. 58-year-old. M, EGPA.
Sleep symptoms: “I wake up tired, just really tired. There doesn’t seem to be any refreshing sleep, no matter how long I try and sleep for”. 
[53-year-old. F, EGPA]
Temperature instability: “I’d have high fevers and night sweats, tremendous night sweats”. 51-year-old. F, EGPA.
Skin problems: “Your skin is so thin that it tears” 04.202. “I had a rash, and I couldn’t get rid of it, breaking out down my arms and chest… it 
drove me crazy”. [68-year-old. F, EGPA]
Earache/hearing difficulties/upper respiratory tract: “I’m coughing up blood and I’ve got bloody noses. I can’t hear on the phone. I’ve lost 
my hearing”. [36-year-old. F, GPA]
Eye symptoms and affected sight: “It was very, very red, very painful like in the back of my eye, it was very painful, and I was sensitive to light, 
I couldn’t read”. [61-year-old. F, GPA]
Cardiorespiratory symptoms: “I could barely walk a few yards down the road without having to stop and really catch my breath”. [48-year-old. 
F, GPA]
Gastrointestinal symptoms: “I had been starting to get a lot of side effects from the prednisone it was really causing havoc in my digestive 
system”. [52-year-old. F, GPA]
Muscle symptoms: “…I just don’t have the muscle power in my legs. And also my arms… its worse when I’m on the steroids”. [53-year-old. F, 
EGPA]
Nerve symptoms: “I couldn’t walk, the sheer agony of the pain was bad as well, I couldn’t use the hand, it went tingly and dropped, the same as 
the foot”. [67-year-old. F, EGPA]
Joint symptoms: “I started having “rotating joint pain”. It would be mostly in my legs, but sometimes in my wrists, in my elbow, but especially in 
my legs”. [64-year-old. M, GPA]
Kidney and urinary tract: “They discovered that there was something wrong with my kidneys which was really quite a shock”. [68-year-old. F, 
MPA]
Appetite: “And then I lost a lot of weight, I lost a stone and a half in weight even though I was trying to eat but I hadn’t got a lot of appetite”. 
[67-year-old. F, EGPA]
Feeling unsteady or faint: “I would take my bath or my shower but my husband would insist that I do it when he was there because I would feel 
faint”. [51-year-old. F, EGPA]
Pain: “And then the joint pains started. And that’s when it became, you know, quite an issue. You know, so I had a real, real problem with pain”. 
[66-year-old. M, GPA]
Abbreviations: ANCA, antineutrophil cytoplasmic antibody; F, female; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; M, male; 
MPA, microscopic polyangiitis.
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Figure 1 Smith’s Salience Indices of patient’s free-listed and ranked terms.
Notes: (A) Terms at AAV diagnosis; (B) terms during AAV remission; (C) terms during AAV flare; (D) comparison across AAV activity states.
Abbreviations: AAV, associated vasculitis; labs, laboratory tests.
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Figure 2 Conceptual framework for the AAV-PRO.
Notes: The scope of the developing measure was defined by the steering committee and evolved during development to include symptom severity, the impact of problems 
and limitations imposed by patients’ ANCA-associated vasculitis and treatment on their work and domestic roles, family and social interactions (including activities and 
interests outside the home), and psychological state.
Abbreviations: AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; PRO, patient-reported outcome.
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be used to measure and compare HRQoL between patients 
with  different chronic conditions, and population norms. A 
combined approach of using disease-specific and generic 
PRO measures may, therefore, be the optimum way of com-
prehensively measuring HRQoL in AAV.49
The 35-item candidate questionnaire will need to be 
shortened to reduce responder burden and optimize feasibility 
within RCTs. The next stage of development will involve a 
large-scale survey to facilitate further item reduction, and 
determine the underlying scale structure and measurement 
properties (reliability, validity, and responsiveness) of the 
final AAV-PRO instrument.
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Supplementary materials
Table S1 Codebook descriptions of individual themes. Collaborative codebook by core qualitative group using consensus methods
Domain Individual themes of 
interest
Description of code
1.  General health 
perceptions
a.  General sense of self and 
wellness
Feeling unwell/under par in a nonspecific or specific sense. Feeling less than normal. 
Perception of self, for example, related to external appearance
b.  Lack of confidence in one’s 
body
General feeling that their body could “let them down” – puts little trust in their body. Feels 
vulnerable or dependent on medical personnel. For example, risk of falling; or sudden onset 
of symptoms when away from help
c. Poor response to treatment Prescribed treatment ineffective (or giving only temporary relief) in general or for particular 
symptoms. Adverse effects
d.  Vulnerability to infection or 
secondary illness
A perception that one is more vulnerable to acquiring infection and is affected for longer 
by infections, for example, colds or secondary conditions such as cancers, diabetes, 
hypertension, and so on
2.  Impact on 
function
a. Level of physical function Cannot do same activities, or same activities to desired level – including sports/interests 
– because of symptoms of vasculitis. A general slowness. Also include discussions of one’s 
ability to exercise and perform to the desired levels
b. Personal mobility Personal mobility problems – relating to physical capabilities, not specific to any activity or 
task. Plus walking locally, for example, to shops or around neighborhood, descriptions of 
being housebound. Does not include transportation
c. Scope for travel Perceived restrictions on traveling away from home because of potential need for informed 
medical care, or risks due to reduced immunity – especially as cannot receive a live 
vaccination
d. Household tasks Work, housework, gardening (yard work). Difficulty with carrying out “normal” everyday 
tasks required to keep home environment in order. Maintenance, cleaning or tidying around 
the house, garden/yard, or work – if that occupies most days
e.  Treatment consumes time/
focus
Effect on time management, for example, sticking to a routine for taking treatment. Lots of 
time taken up with thinking about, or actively engaged with, treatment or monitoring of the 
condition. Dependent on medicine/medical personnel
f. Adaptation Need to do things differently, because of effects of AAV, in order to accomplish tasks. 
Requires walking aids/supports or other devices (eg, hearing aids), to facilitate ADL
g. Hobbies and interests Impact on (loss of) hobbies/interests (not necessarily social) due to AAV. Could include 
range of things like gardening, playing an instrument, amateur dramatics, dancing, and stamp 
collecting. Might also include activities/interests involving technology: computer, camera, and 
so on
h. Use of everyday transport Issues relating to the ability to get around in vehicles – cars, trains, busses, and so on
i. Eating and drinking Finds it hard to eat: difficulties swallowing, fills up quickly. Difficulties with certain foods – 
having to be careful with what they eat. Physical difficulty of getting food/drink to mouth. 
Restriction in alcohol
j. Everyday technology Problems with using telephone, television, and so on – chiefly because of sensory problems 
(sight/hearing)
k. Washing self Difficulty with washing (all over) – mainly because of hand arm function
l. Dressing and undressing Difficulty with putting on particular clothes avoids some or needs help because of effect of 
AAV
3. Psychological a.  Uncertainty/concerns about 
future
Concern about what might happen to self or dependents if the condition (or ability to cope) 
worsens including flares or shortened life/death. Difficulties or changes in relation to future 
plans
b. Fear, anxiety, stress Easily or acutely becomes fearful or anxious; or has generalized feeling of anxiety: low 
threshold (since AAV). Cannot cope with any extra stress – sense that they have no spare 
capacity for dealing with stresses in life. Generalized feeling of “being a worrier” – worries 
creep into most situations or thoughts – implies this is not normal for them (i.e., compared 
to past or compared with how they have tended to think of themselves in the past)
c. AAV dominates Concerns or uncertainties are AAV or related symptoms serving as a barrier to getting on 
with, or enjoying, life. Feeling as though life has been put on hold. AAV dominates thoughts. 
A feeling of loss of control over one’s own life – due to unpredictability of AAV – and its 
severity and/or demands of treatment
(Continued)
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Domain Individual themes of 
interest
Description of code
d. Self-efficacy Attitude to disease. Feeling that life is a struggle – weighed down [by symptoms ± low energy] 
but battling on against it OR conversely having a strong sense of self-efficacy
e. Information and knowledge Descriptions of the presence or absence of information about vasculitis (what it is like, 
prognosis, treatments). This node assumes that the person knows they have vasculitis. Any 
content speaking more specifically to uncertainty/fear about the future should be coded at 
uncertainty
f. Support Descriptions of the person’s perceived level of support – could relate to social relationships, 
a relationship with god/religion
g. Depression low mood Aware of overt depression or perceived difficulty with feeling positive – constant or 
intermittent (but there in the background). Constant concerns about/coping with AAV 
removes fun and enjoyment from everyday life. Life has little purpose. Realities of living with/
concerns about/coping with AAV can affect fun and enjoyment from everyday life
h. Anger and irritation Either due to frustration with disease or its treatment or direct effects of medication, for 
example, steroids
4.  Social 
perceptions
a.  Visibility of condition or side 
effects
Feeling self-conscious or embarrassed about a sign/symptom of the condition or treatment 
obvious to other people
b.  Empathy and emotional 
connections
Perception that others (partner, family, friends) do or do not understand (how bad/ill/tired 
they feel). Can be coupled with reluctance to explain too much detail to others (thereby 
compounding the problem) or thinking that others do not believe them. May socialize more 
with others who have vasculitis – who understand
c.  Source of other people’s 
worry
Perception that friends or family are anxious on their behalf – or are worried that they might 
become “a responsibility”/burden. Or might be contagious
5. Social contact a. Impact on social life Content relating to less energy for socializing, reduced social contact in person, improved 
social relationships, and social isolation (vulnerability, loss of confidence in social situations)
b.  Social activities and 
participation
Unable to engage in social activities that the person wants to or was doing, before the illness 
struck, for example, sports and community participation including organized religion
c.  Adaptations to facilitate 
social life
AAV-related difficulties (eg, mobility problems/sensory impairment/fatigue) mean that social 
occasions require pacing or special planning
d. Quality of communication Impaired hearing/voice problems make communications difficult
e.  Sex and intimate 
relationships
Difficulties within relationships and with sex either because of AAV or its treatments
6. Social role a. Occupation or finances Worry concerned with their ability to do/or get back to doing, their job (“pull their weight”); 
worries about losing their job – because of effects of AAV on their ability to do their specific 
type of work, or any kind of work (“hold down a job”). Might include financial worries – if 
they were unable to continue in work (or to the same level). Loss of income – perhaps 
additional costs incurred, for example, house or transport adaptations, because of AAV. 
Could also include unpaid work
b. Family and family planning Worry about the effect that their AAV is having on their family: changing roles (their 
increased dependency); how family will manage if their work is affected (reduced/lost) or if 
they die. Feeling like a burden on their family. Effects on decisions about family size. Increasing 
stress and conflict within family
c. Dependency on others Needs help from others/partner to do certain tasks/go outside the home (may be contrasted 
with former role where others were more dependent on them)
d. Role identity and status Unable to be helpful/useful to others (as in the past) – associated with a sense of letting 
others down as it relates to significant others, family, or work associates. Change in status at 
work or in society
7. Symptoms a. Fatigue Fatigue, exhaustion, or energy drain, which can be intermittent, sudden, or persistent/
constant. Has “normal” level of energy some (hours or days) of the time, then suddenly 
overcome with fatigue/tiredness/weakness. Or persistent lack of energy, fatigue/tiredness/
weakness over many days, weeks, or months
b.  Cognition and poor 
concentration
Difficulties with focusing on a topic for any length of time. Generally feels distracted or 
thoughts “drift off” “in a fog.” Trouble making decisions and understanding others or 
situations
c.  Issues related to body 
weight
Weight loss, gain, or distribution, causing concern – could be secondary to lost appetite or 
steroids
Table S1 (Continued)
(Continued)
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Domain Individual themes of 
interest
Description of code
d. Sleep symptoms Difficulty getting to sleep, staying asleep, getting enough sleep. For whatever reason (including 
psychological or physical discomfort). Difficulties with sleeping – either getting off to sleep, 
or persistent or early waking – aggravating tiredness – for whatever reason (including 
psychological or physical discomfort)
e. Temperature instability Sweating, shivering, including night sweats: excessive sweating at night – often while asleep – 
for no good reason
f. Skin and nail problems Abnormal rash/marks/blotches/lumps/ulcers, affecting the skin, including signs of bleeding 
into skin (including under nails). Added swelling of the skin and hair changes and mucous 
membranes and Raynaud’s syndrome
g.  Earache and hearing 
difficulties
Ear infections/sense of blocked ears/impaired hearing/need for hearing aid/painful ears 
(internally)/feeling of pressure
h. Upper respiratory tract Constant feeling of nose or sinuses being blocked, congested, pressured, or running. Bleeding 
– in quantity – from the nose, on more than one occasion. Sore throat or problems with 
voice. Sinus infections or repeated need for treatment of some kind
i.  Eye symptoms and affected 
sight
Eye pain or irritation. Impaired or lost sight. Bleeding into eye. Cataracts. Threat/fear of losing 
sight. Can also include watery, itchy, or dry eyes
j. Cardiorespiratory symptoms Shortness of breath/sense that breathing is labored/pain associated with breathing. Wheezing 
or coughing. Coughing up blood. Chest pains
k. Gastrointestinal symptoms Diarrhea, vomiting, nausea, bloating
l. Muscle symptoms Pain perceived as coming from muscle(s) related or unrelated to activities. Including cramps 
including aches or pains in lower or upper back. Perceived muscle weakness or tiredness and 
less ability to control specific muscle actions. If related to lower limbs may provoke falls
m.  Numbness and nerve 
symptoms
Hypersensitivity, burning pains, or numbness along the path of a nerve
n. Joint symptoms Ache/pain, stiffness, swelling (of joints), range of movement, increased warmth perceived as 
coming from, or in, joints – one joint or many. When at rest or following activities
o. Kidney and urinary tract Passing blood in urine or frequency or dysuria (pain or difficulty passing water) and kidney 
problems
p. Appetite Loss of appetite. No interest in food or finds it hard to eat: difficulties swallowing, fills up 
quickly. (new) Difficulties with certain foods – having to be careful with what they eat
q. Sense of taste References to inability to taste food
r. Feeling unsteady or faint Has difficulty maintaining balance when either standing on one spot for any length of time, 
or after initially standing up. Or gait affected. Possibly associated with sense of dizziness or 
lightheadedness. Also include descriptions of feeling faint or fainting
s. Pain Pain in arms and hands, pain in feet and legs: low-grade aching through to severe. Intermittent 
or persistent/constant. Could relate to muscles, joints, or nerves, and should be double 
coded as appropriate. Any mention of pain in the face, upper sinuses, or head. Generalized 
pain without specified cause or location
Abbreviations: AAV, antineutrophil cytoplasmic antibody-associated vasculitis; ADL, activities of daily life.
Table S1 (Continued)
Box S1 Translatability of the questionnaire
•	 The translatability of the questionnaire refers to whether items can be meaningfully translated into other languages in the future.50
•	 First, a concept elaboration document is produced, which clarifies any ambiguities or nuances within the candidate items and instructions.
•	 For each item and instruction, concepts and wording are then checked to ensure equivalence between the original and target language, and 
whether they remain linguistically and culturally appropriate. A sample of different types of languages is tested.
•	 Arabic (Egypt), Finnish (Finland), German (Germany), Greek (Greece), Russian (Russia), Spanish (Argentina), and Xhosa (South Africa) were the 
languages tested in this study.
•	 The questionnaire items were then refined to enable better cultural and linguistic equivalence across future translations, and thereby to improve 
the measure’s performance when used in international studies.
•	 A translatability assessment does not go as far as conducting full-scale translation/back-translation process, with testing for validity in another 
language(s). This is for the future (once the number of questionnaire items has been finalized) and would require a full study for each language. 
However, the translatability assessment that was undertaken should ensure that future translations are more straightforward and will better 
facilitate equivalence.
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